Recent research indicates that individuals following the Dietary Approaches to Stop Hypertension (DASH) diet can do so safely without significantly impacting their potassium levels, even when taking common blood pressure medications. This finding is especially relevant for those prescribed medications known to potentially increase potassium levels, such as ACE inhibitors and potassium-sparing diuretics. The study,…

Recent research highlights that women experience pain more frequently than men, with significant increases in prevalence occurring before the age of 55. This findings come from a comprehensive global study conducted between 1990 and 2025, involving over 6 million participants across 118 countries. The study, published in the journal Nature Medicine, reveals that pain is…

Recent research has highlighted a concerning trend among users of GLP-1 medications, such as Ozempic and Wegovy, indicating that these drugs may be linked to nail detachment and discoloration. The study, presented at the European Academy of Dermatology and Venereology (EADV) Congress in Vienna, found that individuals using GLP-1 drugs reported nail detachment more than…

Recent research has highlighted the effectiveness of orforglipron (marketed as Foundayo), an oral GLP-1 medication, in promoting weight loss among women, regardless of their menopausal status. This finding is particularly significant considering the challenges many women face in losing weight during and after menopause due to hormonal changes, primarily the decline in estrogen levels. The…

Recent findings from the OCTANE study suggest that individuals with overweight or obesity may experience additional weight loss after switching from injectable GLP-1 medications to the Wegovy pill (semaglutide). Conducted in a real-world setting, this research indicates that participants lost an average of 4.1% of their body weight over a three-month period following the transition….

Recent research indicates that increasing the dosage of Ozempic may be associated with a reduced risk of major adverse cardiovascular events (MACE) compared to switching to Mounjaro. This finding comes from a comprehensive analysis presented at the European Association for the Study of Diabetes Annual Meeting in Milan, Italy, which examined real-world data from over…

The popularity of BPC-157, often referred to as the “Wolverine” peptide, has surged in recent years among individuals seeking relief from pain and quicker recovery from injuries. Despite its rising fame, evidence supporting its effectiveness and safety in humans remains limited. In July, an FDA advisory panel recommended easing restrictions on BPC-157 and other peptides,…

Recent findings suggest that reducing the intake of ultra-processed foods (UPFs) could alleviate symptoms of depression. A study published in *JAMA Psychiatry* on September 23 revealed that participants who significantly cut back on UPFs reported improved mental health outcomes. Ultra-processed foods are typically industrially manufactured products containing ingredients that are not commonly found in home…

A recent study has highlighted a concerning link between sleep quality and health risks, showing that inadequate REM (rapid eye movement) and deep sleep can increase susceptibility to various diseases. Conducted using data from wrist trackers worn by 95,000 participants, the research revealed that more REM and deep sleep correlates with a significantly lower risk…

A significant recall has been announced for a commonly prescribed blood pressure medication, chlorthalidone, affecting over 13,500 bottles nationwide. The U.S. Food and Drug Administration (FDA) revealed that the recall was initiated by Inventia Healthcare Limited due to the tablets failing to meet critical lab dissolution specifications. On September 3, 2026, the recall was voluntarily…